Every encounter is a reunion, the temporary separation is for a better meeting.
After three years of postponement, CPHI China opened on 19th June in Shanghai New International Expo Center and came to a successful conclusion on 21st June.
This year, Gene Biocon is still at booth E3E82 in the bio-pharmaceutical area and has brought self-developed quality products like Recombinant Trypsin (cell culture grade, pharmacopeia grade and 1:250), Recombinant Lysyl Endopeptidase (biochemical grade and M.S. grade), Liraglutide, Insulin Aspart, Insulin Degludec, etc.
During this exhibition, Gene Biocon was known for the highly active and quality biological raw materials and comprehensive finished product OEM/ODM/CDMO service, which has attracted many visitors to communicate and discuss cooperation. It has injected new vitality into the continuous development of the company's business and market development.
Insulin APIs
The Insulin degludec and semaglutide were welcomed and attracted many customers to learn about them.
Gene Biocon manufactures insulin degludec, insulin aspart, semaglutide and liraglutide. The medicine of insulin degludec for diabetes independently researched by our R&D department has passed the first phase of clinical testing already.
So far, CPHI China 2023 came to a successful conclusion!
Thanks for everyone's visit and support!
Hoping to meet you at next year's CPHI China!
